Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Topical sunscreen may be effective in preventing skin rash caused by treatment
with drugs such as erlotinib or cetuximab. It is not yet known whether topical sunscreen is
more effective than a placebo in preventing skin rash in patients receiving drugs such as
erlotinib or cetuximab for cancer.
PURPOSE: This randomized phase III trial is studying topical sunscreen to see how well it
works compared with a placebo in preventing skin rash in patients receiving drugs such as
erlotinib or cetuximab for cancer.